期刊文献+

磷酸川芎嗪鼻用pH敏感型原位凝胶的处方优化 被引量:16

Prescription Optimization of Ligustrazine Phosphate pH-sensitive in Situ Gel in Nasal
暂未订购
导出
摘要 目的优化磷酸川芎嗪鼻用pH敏感型原位凝胶的制备工艺。方法采用星点设计法考察卡波姆和羟丙基甲基纤维素的用量对制备工艺的影响,以黏度和5h的药物释放量作为考察指标,对结果进行线性方程和二次多项式方程拟合,效应面法选取最佳工艺条件进行预测分析。结果从复相关系数上看,各指标二项式拟合方程均优于多元线性回归方程,优选的最佳条件为卡波姆的用量为0.55%,羟丙基甲基纤维素的用量为1.4%。结论星点设计-效应面法适用于磷酸川芎嗪鼻用pH敏感型原位凝胶的工艺优化,所建立的数学模型预测性良好。 Objective To optimize the process of Ligustrazine Phosphate pH-sensitive in situ gels in nasal process.MethodsCentral composite design was used to observe the effect of the amount of carbopol and HPMC on preparation process with of viscosity and 5 h drug release as indicators,the results of linear equations and quadratic polynomial equation fitting,response surface method to select the optimum conditions for predictive analysis.ResultsAccording to multiple correlation coefficient,the indicators were better than the binomial equation fitting multiple linear regression equation,the best conditions for the optimization was the amount of carbopol 0.55%,the amount of HPMC 1.4 %.ConclusionThe central composite design and response surface method are useful for the optimization of preparing Ligustrazine phosphate pH-sensitive in situ gel in nasal.The estimation of the established model is good.
出处 《时珍国医国药》 CAS CSCD 北大核心 2010年第9期2296-2298,共3页 Lishizhen Medicine and Materia Medica Research
基金 国家自然科学基金(No.30801551 30672669) 广东省自然科学基金(No.8451052005001186)
关键词 星点设计-效应面法 磷酸川芎嗪 PH敏感 原位凝胶 卡波姆 羟丙基甲基纤维素 CCD-RSM Iigustrazine phosphate PH-sensitive In situ gel Carbopol HPMC
  • 相关文献

参考文献8

二级参考文献57

  • 1王鹏,王玉珠,沈建民.均匀设计及其在药学中的应用[J].沈阳药学院学报,1989,6(4):297-305. 被引量:74
  • 2唐星,王成伟.常用生物黏附性高分子材料物理性质的比较试验[J].中国药学杂志,2005,40(5):361-364. 被引量:12
  • 3张英姿.杀精子剂-壬苯醇醚研究进展[J].滨州医学院学报,1995,18(2):95-97. 被引量:2
  • 4王剑红,陆彬,胥佩菱,包定元,张自然.肺靶向米托蒽醌明胶微球的研究[J].药学学报,1995,30(7):549-555. 被引量:25
  • 5Cohen S, Lobel E, Trevgoda A, et al. A novel in situ-forming ophthalmic drug delivery systems from alginates undergoing gelation in the eye [J] .J Controlled Release, 1997,44(2-3) :201.
  • 6Gurny R, Boye T, lbrahim H. Ocular therapy with nanoparticulate systems for controlled drug delivery [J ]. J Controlled Release, 1985,2(3 ): 353.
  • 7Srividya B, Cardoza RM, Amin PD. Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system [ J ]. J Controlled Release ,2001,73(2) :205.
  • 8Lin HR, Sung KC. Carbopol/pluronic phase change solutions for ophthalmic drug delivery [J ]. J Controlled Release ,2000,69(3 ) :379.
  • 9Yun MO,Choi HG,Jung JH,et al. Development of a thermo-reversible insulin liquid suppository with bioavailability enhancement [J]. Int J Pharm, 1999,189(2) : 137.
  • 10Desai SD,Blanchard J. Evaluation of Pluronic F127 sustained-release ocular delivery systems for pilocarpine using the albino rabbit eye model [J ]. J Pharm Sci, 1998,87(10) : 1190.

共引文献754

同被引文献174

引证文献16

二级引证文献86

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部